Saprisartan

Identification

Generic Name
Saprisartan
DrugBank Accession Number
DB01347
Background

Saprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan. It is very likely that slow dissociation kinetics from the AT1 receptor underlie insurmountable antagonism 1.

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 611.431
Monoisotopic: 610.049723164
Chemical Formula
C25H22BrF3N4O4S
Synonyms
  • Saprisartan

Pharmacology

Indication

Saprisartan is used in the treatment of hypertension and heart failure.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

By inhibiting the angiotensin II receptor, this drug leades to a decrease in sodium reabsorption and a decrease in vasoconstriction. This has the combined effect of decreasing blood pressure.

Mechanism of action

Saprisartan is a selective, potent, orally active and long-acting nonpeptide Angiotensin II type 1 (AT1) receptor antagonist. Saprisartan blocks the renin-angiotensin-aldosterone system (RAAS) at the level of the AT1 receptor that mediates most, if not all, of the important actions of Ang II. Saprisartan binds reversibly to the AT1 receptors in vascular smooth muscle and the adrenal gland. As angiotensin II is a vasoconstrictor, which also stimulates the synthesis and release of aldosterone, blockage of its effects results in decreases in systemic vascular resistance. AT1 receptor antagonists avoid the nonspecificity of the Ang I converting enzyme (ACE) inhibitors.

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbaloparatideAbaloparatide may increase the hypotensive activities of Saprisartan.
AcebutololAcebutolol may increase the hypotensive activities of Saprisartan.
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Aceclofenac.
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Saprisartan is combined with Acetylsalicylic acid.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Saprisartan potassiumT28707PG7T146613-90-3IASZJGRIPLTJMA-UHFFFAOYSA-N

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 2-arylbenzofuran flavonoids. These are phenylpropanoids containing the 2-phenylbenzofuran moiety.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
2-arylbenzofuran flavonoids
Sub Class
Not Available
Direct Parent
2-arylbenzofuran flavonoids
Alternative Parents
2-phenylbenzofurans / Sulfanilides / 1,2,4,5-tetrasubstituted imidazoles / 2-heteroaryl carboxamides / Carbonylimidazoles / Organosulfonamides / Aryl bromides / Organic sulfonamides / N-substituted imidazoles / Aminosulfonyl compounds
show 14 more
Substituents
1,2,4,5-tetrasubstituted imidazole / 2-arylbenzofuran flavonoid / 2-heteroaryl carboxamide / 2-phenylbenzofuran / Alkyl fluoride / Alkyl halide / Aminosulfonyl compound / Aromatic heteropolycyclic compound / Aryl bromide / Aryl halide
show 35 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
HS64NG1G69
CAS number
146623-69-0
InChI Key
DUEWVPTZCSAMNB-UHFFFAOYSA-N
InChI
InChI=1S/C25H22BrF3N4O4S/c1-2-19-31-21(14-8-9-14)22(24(30)34)33(19)12-13-7-10-18-16(11-13)20(26)23(37-18)15-5-3-4-6-17(15)32-38(35,36)25(27,28)29/h3-7,10-11,14,32H,2,8-9,12H2,1H3,(H2,30,34)
IUPAC Name
1-({3-bromo-2-[2-(trifluoromethanesulfonamido)phenyl]-1-benzofuran-5-yl}methyl)-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxamide
SMILES
CCC1=NC(C2CC2)=C(N1CC1=CC2=C(OC(=C2Br)C2=CC=CC=C2NS(=O)(=O)C(F)(F)F)C=C1)C(N)=O

References

General References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [Article]
Human Metabolome Database
HMDB0015437
PubChem Compound
60921
PubChem Substance
46508176
ChemSpider
54892
ChEMBL
CHEMBL305544
ZINC
ZINC000003919581
Therapeutic Targets Database
DAP001257
PharmGKB
PA164746338

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0151 mg/mLALOGPS
logP5.89ALOGPS
logP3.53Chemaxon
logS-4.6ALOGPS
pKa (Strongest Acidic)2.27Chemaxon
pKa (Strongest Basic)4.91Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area120.22 Å2Chemaxon
Rotatable Bond Count8Chemaxon
Refractivity137.15 m3·mol-1Chemaxon
Polarizability54.2 Å3Chemaxon
Number of Rings5Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.647
Caco-2 permeable-0.6148
P-glycoprotein substrateSubstrate0.5611
P-glycoprotein inhibitor INon-inhibitor0.6454
P-glycoprotein inhibitor IINon-inhibitor0.5279
Renal organic cation transporterNon-inhibitor0.8625
CYP450 2C9 substrateNon-substrate0.653
CYP450 2D6 substrateNon-substrate0.7866
CYP450 3A4 substrateSubstrate0.5105
CYP450 1A2 substrateNon-inhibitor0.6561
CYP450 2C9 inhibitorInhibitor0.6267
CYP450 2D6 inhibitorNon-inhibitor0.7996
CYP450 2C19 inhibitorInhibitor0.5274
CYP450 3A4 inhibitorNon-inhibitor0.5167
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8837
Ames testNon AMES toxic0.5853
CarcinogenicityNon-carcinogens0.6378
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5781 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9673
hERG inhibition (predictor II)Inhibitor0.6568
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0lea-6500390000-e400299fe00d75260a2e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03di-0000019000-39822abe404188be17f6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-2000059000-4a45d3ce92dec0db4b06
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-0000089000-ce219980787fffe0fef3
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0udi-0207393000-04844f6393fb87977183
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-5200089000-24c45fa6bf3e595670ab
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-03mi-2900010000-4ea636cf976f77eed6f5
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-238.841073
predicted
DarkChem Lite v0.1.0
[M-H]-201.50175
predicted
DeepCCS 1.0 (2019)
[M+H]+238.780073
predicted
DarkChem Lite v0.1.0
[M+H]+203.89732
predicted
DeepCCS 1.0 (2019)
[M+Na]+238.803573
predicted
DarkChem Lite v0.1.0
[M+Na]+209.76677
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Timmermans PB: Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. [Article]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]

Drug created at June 30, 2007 18:15 / Updated at February 21, 2021 18:51